|
 |
ValcyteThis page contains recent news articles, when available, and an overview of Valcyte but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Valcyte (when available) Ganciclovir is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), Ganciclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts Ganciclovir into Ganciclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. in vitro, Ganciclovir triphosphate stops replication of herpes viral DNA. When used as a substrate for viral DNA polymerase, Ganciclovir triphosphate competitively inhibits dATP leading to the formation of 'faulty' DNA. This is where Ganciclovir triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand. For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Mechanism Of Action: Ganciclovir stops replication of herpes viral DNA in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase. Ganciclovir targets HSV and VSV thymidine kinase News Articles on Ganciclovir Middel tegen CMV bij getransplanteerde kinderen goedgekeurd - Oct 20, 2009 Om dit te voorkomen kunnen ze een virusremmer slikken, zoals Valcyte (valganciclovir). Hoewel het bij kinderen in de praktijk al wel gebruikt werd, ... NierNieuws.nl India's Ranbaxy gets FDA nod for Valcyte generic - Jun 25, 2008 MUMBAI, June 25 (Reuters) - India's Ranbaxy Laboratories Ltd (RANB.BO) said it had received tentative approval from the US Food and Drug Administration for ... Reuters Roche urged to cut drug price to stop blindness - Dec 3, 2007 VX) to cut prices for its antiviral Valcyte in developing countries, ... The disease can be diagnosed quite easily and Valcyte is an effective treatment, ... Reuters Madras HC sets aside Valcyte patent - Dec 3, 2008 Mumbai: A Madras high court bench on Tuesday set aside the patent granted to Swiss drug maker F. Hoffman-La Roche AG for its anti-infection drug ... Livemint Cipla, Roche may now spar over Valcyte - Jul 10, 2008 New Delhi / Mumbai: Mumbai-based Cipla Ltd is looking to launch a cheaper copycat version of Valcyte,a patented drug from the stable of Swiss firm F ... Livemint New Treatment Guidelines Recommend VALCYTE(R) for AIDS-Related … - Jan 31, 2005 NUTLEY, NJ, Jan. 31 /PRNewswire/ -- VALCYTE(R) (valganciclovir), a potent oral treatment for AIDS-related cytomegalovirus (CMV) retinitis, received positive ... RedOrbit Ranbaxy challenges decision to grant patent for Valcyte - Feb 11, 2008 Mumbai: Adding fuel to an existing patent controversyinvolving Swiss drug maker F Hoffman-La Roche Ltd's anti-infection drug Valcyte in India, the country's ... Livemint Roche may drag Cipla to Madras high court - Aug 6, 2008 Swiss drug maker F Hoffmann-La Roche Ltd may move the Madras high court against patent infringement of its anti-infection drug Valcyte by Cipla Ltd, ... Livemint … Release: New Treatment Guidelines Recommend VALCYTE(R) for AIDS- … - Jan 31, 2005 New Treatment Guidelines Recommend VALCYTE(R) for AIDS-Related CMV Retinitis; - New Opportunistic Infections Guidelines Released by CDC, NIH, and HIVMA/IDSA ... Pay-Per-View - PR Newswire - HighBeam Research Valcyte as effective as ganciclovir in CMV.(cytomegalovirus)(Brief... - May 14, 2007 Swiss drug major Roche says that the results of a trial of its oral antiviral Valcyte (valganciclovir), designed to treat cytomegalovirus infection in ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Ranbaxy gets US FDA nod for Valcyte generic - Jun 25, 2008 Mumbai: India's Ranbaxy Laboratories Ltd has received tentative approval from the US Food and Drug Administration for the generic version of Roche's ... Livemint Roche wins trademark case against Cipla - Dec 11, 2008 The Madras High Court had recently set aside the patent covering valcyte on grounds of procedural irregularity and asked the patent office to consider the ... Daily News & Analysis MSF urges Roche to cut drug price to stop blindness - Nov 30, 2007 VX) to cut prices for its antiviral Valcyte in developing countries, ... The disease can be diagnosed quite easily and Valcyte is an effective treatment, ... Reuters Ranbaxy gets nod to sell generic AIDS drug - Jun 26, 2008 Roche's patent for Valcyte will end in 2015. Roche has already sought legal action against Ranbaxy citing alleged patent infringement on valganciclovir. ... Business Standard Cytomegalovirus; Treatment for AIDS-related cytomegalovirus receives ... - Mar 1, 2005 The guidelines state that VALCYTE is the preferred treatment for patients ... As a potent oral treatment, VALCYTE is more convenient for patients and does ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Cytomegalovirus; Treatment for AIDS-related cytomegalovirus receives ... - Mar 2, 2005 The guidelines state that VALCYTE is the preferred treatment for patients ... As a potent oral treatment, VALCYTE is more convenient for patients and does ... Pay-Per-View - Immunotherapy Weekly - Factiva, from Dow Jones Cytomegalovirus; Treatment for AIDS-related cytomegalovirus receives ... - Mar 5, 2005 The guidelines state that VALCYTE is the preferred treatment for patients ... As a potent oral treatment, VALCYTE is more convenient for patients and does ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Challenge to Indian patent on Roche's Valcyte by local firms. - Jul 7, 2008 Challenge to Indian patent on Roche's Valcyte by local firms. Indian generic drugmakers Cipla, Matrix Laboratories and HIV/AIDS advocacy group Delhi Network ... $9.94 - Pharma Marketletter - Alacra Store MSF Calls On Roche To Reduce Cost Of Oral Antibiotic To Prevent … - Dec 6, 2007 Roche has offered to provide aid agencies with Valcyte at a reduced cost of ... MSF pays more than $10000 for a four-month course of Valcyte per patient in ... Medical News Today - Medical News Today (press release) :: æ–°å?Žç½‘:: - 地方è?”æ’ - Apr 19, 2005 ...æ?®æ‚‰ï¼Œç½—æ°?用于所有实体器官移æ¤?高å?±å?—者的CMV疾病的预防è?¯å“?万赛维（Valcyte），将 在年内在ä¸å›½ä¸Šå¸‚。 黎磊石å?Œæ—¶æŒ‡å‡ºï¼Œç”±äºŽç»„织é…?型与器官ä¿?å˜æ–¹æ³•çš„ä¸?æ–改进ã€?强 ... æ–°å?Žç½‘ … para la enfermedad por CMV con Valcyte podrÃa proporcionar comodidad... - May 8, 2007 Madrid, 8 de mayo de 2007.- Los resultados del estudio VICTOR, presentados hoy en el American Transplant Congress de San Francisco (EEUU), muestran que ... acceso.com New hope for sufferers of chronic fatigue - Feb 4, 2007 Last year Manson began a six-month course of Valcyte, which is approved to treat transplant patients to prevent viral infection. At first he felt worse. ... Independent Online Cipla gets 2 weeks to reply in patent row with Roche - Sep 30, 2008 The Valcyte case is the second suit filed against Cipla by Roche this year. ... Valcyte, a formulation of valgancyclovir, is used for treating patients ... Livemint Group moves HC against patent grant to Roche - Nov 18, 2008 The lawyers body had filed a pre-grant opposition in the case of Valcyte on ... Mint had previously reported that Valcyte faces at least five post-grant ... Livemint Herpes and respiratory antivirals: Avaian flu catalyst for maintaining... - Nov 10, 2005 While Valcyte benefits from oral availability for the entire course of treatment and is further associated with higher efficacy, a crucial factor underlying ... Free with registration - M2 Presswire - AccessMyLibrary.com Article: Patient's muscle cells used to repair heart - Oakland... - Dec 16, 2007 Article: One-Year Pivotal Study Results Show Valcyte(TM) Comparable to ... ... Valcyte is the oral ... CMV disease in solid organ transplant recipients was ... Pay-Per-View - Oakland Tribune - HighBeam Research Ranbaxy Laboratories Limited получила предварительное разрешение … - Jun 30, 2008 перенеÑ?ших транÑ?плантацию почек, Ñ?ердца и поджелудочной железы. Valganciclovir Hydrochloride Ñ?влÑ?етÑ?Ñ? дженериковым аналогом препарата Valcyte. ФармацевтичеÑ?кий веÑ?тник Extra lange kuur bij meegetransplanteerd virus is beter - Dec 22, 2008 Alle 326 virus-negatieve patiënten die een nier kregen van een virus-positieve donor, kregen 100 dagen de virusremmer valganciclovir (Valcyte). ... NierNieuws.nl FEATURE-Small trial stirs hope for chronic fatigue patients - Jan 15, 2007 Last year Manson began a six-month course of Valcyte, which is approved to treat transplant patients to prevent viral infection. At first he felt worse. ... Reuters Live Chat with Author Dorothy Wall - April 19, 2007 - Apr 19, 2007 Dorothy Wall: I think the Valcyte trial at Stanford is very exciting. ... The preliminary results of a small trial of Valcyte were very encouraging, and I, ... ProHealth Roche sues Ranbaxy over antiviral drug - May 5, 2006 Sales of Valcyte and a related drug called Cymevene reached 394 million Swiss francs ($318.7 million) last year. A Ranbaxy spokesperson refused to comment ... Financial Express Article: JMP impact study; TRANSPORT.(News) - The Birmingham Post ( … - May 27, 2008 Against Cytomegalovirus in Transplant (IMPACT) study showed that 200-day Valcyte prophylaxis ... help make a difference." About the IMPACT Study This ... Pay-Per-View - Birmingham Post - HighBeam Research Roche 2004 annual report: therapeutic areas - transplantation. - Jan 27, 2005 Combined sales of Valcyte and Cymevene showed solid growth of 22% in 2004 as Valcyte ... Valcyte has now been launched in most major markets in its new ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Roche files 2 pleas against Cipla copycat drug - Sep 27, 2008 Valcyte, which goes by the generic or chemical name 'Valganciclovir', is used to prevent eye infections for people with lower immune power. ... Rediff Pfizer scrip surges on AIDS drug patent win - Dec 12, 2007 Patient groups are opposing the patent granted to Valcyte. Bloomberg adds: Winning a patent helps Pfizer sell the drug free from competition from low-cost ... Business Standard Lawyer group to challenge patent for Roche's anti-HIV drug - Sep 26, 2007 Valganciclovir, sold by Roche as Valcyte internationally, was granted ... Valcyte is the fifth Roche drug that has been granted patents in India since 2006. ... Livemint Un grupo selecto de expertos mundiales se reúnen en Santiago de … - Jun 24, 2005 Valcyte (valganciclovir) es un producto joven, en pleno desarrollo, con un papel vital en ... Valcyte ha sido desarrollado para superar las limitaciones del ... acceso.com Johnson v. Correctional Mecical Services, Inc., No. 4:06-CV-137... - Oct 1, 2007 In a related objection, Plaintiff claims medical personnel will not prescribe him Valcyte, a prescription drug he believes is necessary to treat HHV6-A. The ... $2.95 - U.S. District Court, Western District... - VersusLaw Surgeon changes study of brain tumors - Oct 6, 2008 In San Francisco, some of Cobbs' patients who are taking Valcyte, an anti-CMV drug are experiencing results similar to those of Mitchell's patients. ... San Francisco Chronicle Now, Ranbaxy seeks peace with Takeda - Jun 22, 2008 The other patent-related litigations, apart from the five pending Lipitor litigations Ranbaxy has with Pfizer in Europe, are on drugs like Allegra, Valcyte ... Business Standard Valganciclovir is safe and effective as pre-emptive therapy for CMV … - Mar 13, 2006 ...outpatients with an absolute granulocyte count above 500/mm 3 and who did not have severe gastrointestinal GVHD started oral VGC (Valcyte ® ) at a dose ... Nature.com Supplies unlikely to be affected as Roche, Cipla lock horns over HIV... - Dec 14, 2008 Roche's 60-tablet pack of Valcyte costs the consumer Rs 43000, or about Rs 716 a tablet, an industry representative said. Cipla's generic version is priced ... Hindu Business Line Patent denied in US, but granted in India - Jan 15, 2008 ...(India) Pvt. Ltd, agreed the Valcyte patent application in India made identical claims as in its 1994 US application, but insisted no rules had been ... Livemint Article: DISMISSAL UPHELD.(News) - The Kentucky Post (Covington, KY) … - Feb 1, 2007 Against Cytomegalovirus in Transplant (IMPACT) study showed that 200-day Valcyte prophylaxis ... help make a difference." About the IMPACT Study This ... Pay-Per-View - Kentucky Post - HighBeam Research Press Release: Cylex Study of Pediatric Immune Systems Will Improve … - Apr 11, 2005 Article: U.S. FDA Approves New Indication for Valcyte(TM); Valcyte ... ... Valcyte is the oral ... pancreas and heart transplant patients. ... Pay-Per-View - PR Newswire - HighBeam Research 抗病毒è?¯ç‰©ç›¯ä½?禽æµ?æ„Ÿ - Sep 18, 2006 ...ä¸Žè‘›å…°ç´ å?²å…‹ä¸€æ ·,ç½—æ°?在该è?¯äºŽ2002~2005年间陆ç»å¤±åŽ»ä¸“利ä¿?护之际,通过推出å?Žç»äº§å“? 缬更昔洛韦(Valcyte/万赛维),æ?¥åº”对仿制è?¯çš„竞争,防æ¢è¯¥è?¯é”€å”®é¢?出现滑å?¡ã€‚ ... æ?œç‹? A Protein from a Common Smoldering Virus Linked to Chronic Fatigue … - Jun 23, 2008 According to Dr. Kondo, drugs like Valcyte combat active replication but can't completely control low-level smoldering. "To cure the diseases, ... marketwire.com At Least Half Of All Kidney Transplant Recipients Benefit From Drug... - Aug 12, 2008 Valcyte was developed for the prevention of cytomegalovirus (CMV), ... Oral Valcyte has displaced oral and intravenous ganciclovir as the gold standard for ... Medical News Today - Medical News Today (press release) Press Release: National Foundation for Transplants to Expand Program ... - Oct 15, 2007 Article: U.S. FDA Approves New Indication for Valcyte(TM); Valcyte ... ... Valcyte is the oral pro-drug of Roche's Cytovene(R ... pancreas and heart ... Pay-Per-View - PR Newswire - HighBeam Research Dr. Hans-Joachim Bohm Named President of Roche Palo Alto. - Dec 11, 2006 Medicines discovered at Roche Palo Alto include CellCept(R) (mycophenolate mofetil), Valcyte(R) (valganciclovir) and Naprosyn(R) (naproxen). ... Free with registration - PR Newswire - AccessMyLibrary.com Loislaw Federal District Court Opinions - JOHNSON v. CORRECTIONAL … - Mar 3, 2008 Plaintiff claims that he took the anti-viral drug "Valcyte" for his ... Page 3 When Plaintiff asked to be put back on Valcyte, and even offered to have his ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Roche Launches New Web Site for Organ Transplantation Community - Jul 24, 2006 ...heart and liver transplants; Valcyte(R) (valganciclovir), the leading antiviral used to prevent cytomegalovirus (CMV) infection in high-risk patients ... Genetic Engineering News - Genetic Engineering News (press release) Options for treating ganciclovir-resistant CMV discussed at IDSA … - Oct 16, 2006 The current options are the intravenous drugs ganciclovir (Cymevene), foscarnet (Foscavir) and cidofovir (Vistide), and the oral valganciclovir (Valcyte.). ... Aidsmap Om CMV - Apr 16, 2007 Cymevene og Valcyte er potente midler mot virus (CMV), men nÃ¥r du ikke tar medikamentene inn, kan det ikke være risikabelt Ã¥ hÃ¥ndtere dem pÃ¥ vanlig mÃ¥te. ... Lommelegen.no Many battles ahead - Nov 30, 2006 Roche patent application for antiviral drug Valcyte and GlaxoSmithKline patent applications for antiretroviral drugs Combivir and Abacavir Sulfate. ... pharmabiz.com Controverse over geneesmiddel tegen blindheid... - Jan 1, 2008 ...“Valcyte is een geneesmiddel dat in de eerste plaats dient voor orgaantransplantaties. We verkopen het aan een gunststarief van 304 euro per pakje aan de ... Mondiaal Magazine TRF2 anula sentença que garantia carta patente para medicamento … - Mar 6, 2008 ...o requerimento da Agência no sentido de que fosse feita uma perÃcia com o intuito de provar a ausência de novidade do princÃpio ativo do Valcyte. ... Âmbito JurÃdico - Âmbito JurÃdico (Assinatura) A new clinical study offers hope of a therapy for the UK's 250,000... - Jan 11, 2007 ...have received a grant for over $1 million (more than £50000 pounds) from Roche Pharmaceutical, which manufactures the drug under the brand name Valcyte, ... Times Online India Stocks: GMR, Jet Airways, Ranbaxy, Spice Communications - Jun 25, 2008 India's biggest drugmaker received tentative approval in the US to sell its copy of Roche Holding AG's Valcyte, a medicine that treats eye infections in ... Bloomberg Roche says that supplies of Tamiflu are adequate.(News)(Hoffmann-La … - Oct 27, 2008 Article: Valcyte Cleared.(Hoffmann-La Roche Inc.)(Brief ... ... NUTLEY, N.J. -- Valcyte has been approved by the FDA for the treatment of AIDS-related ... Pay-Per-View - Chain Drug Review - HighBeam Research Press Release: ImmuKnow(R), Cylex's Immune Function Test, Expands … - May 9, 2007 Article: One-Year Pivotal Study Results Show Valcyte(TM) Comparable to . ... "Valcyte was ... in solid organ transplant recipients was filed with ... liver ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Roche Launches New Web Site for Organ … - Jul 24, 2006 ...heart and liver transplants; Valcyte(R) (valganciclovir), the leading antiviral used to prevent cytomegalovirus (CMV) infection in high-risk patients ... Pay-Per-View - PR Newswire - HighBeam Research Roche and Protein Design Labs to Jointly Develop Daclizumab in … - Nov 1, 2005 Valcyte(R) (valganciclovir) was developed for the prevention of cytomegalovirus, a dangerous viral infection associated with transplantation. ... RedOrbit PM urged to make patent process better - Dec 24, 2007 ...patent to Swiss drug multinational F Hoffmann-La Roche Ltd for its anti-infection drug Valcyte, without hearing an opposition filed by a patient group. ... Livemint Cipla, NGO to contest patent grant to Roche - Dec 3, 2007 Valganciclovir, sold by Roche as Valcyte, was invented by the company in 1994. This drug was patented first in the US the same year. ... Livemint HUL, Eureka Forbes slug it out over patent grants - Feb 26, 2008 Valcyte, ignoring a pre-grant opposition by two non-governmental organizations— the Indian Network for People Living with HIV/AIDS and the Tamil Nadu ... Livemint US' Alcon wins case against Ajanta Pharma - Dec 29, 2008 ...in favour of the original trademark holder, notably the same court's order in favour of Swiss major Roche's drug Valcyte against Cipla's drug Valcept. ... Economic Times Controller orders inquiry into Chennai office patent for Roche - Dec 22, 2007 ...which the Swiss drug maker sells under the brand Valcyte, without hearing an opposition filed by a patient group as mandated under Indian patent rules. ... Livemint Stocks to Watch on Wednesday - Aug 6, 2008 F Hoffmann-La Roche may move the Madras High Court against patent infringement of its HIV/AIDS drug Valcyte by Cipla Ltd. This would be a second suit by ... Economic Times Cancer patients group to contest patent for Roche's Herceptin - Dec 12, 2007 ...drug for Hepatitis C that is now being opposed by Wockhardt Ltd; lung cancer drug Tarceva; anti-HIV drug Valcyte and Mircera that treats renal anaemia. Livemint Surge in patents has critics crying foul - Dec 31, 2007 Such a claim, where the opponents of Roche's Valcyte patent allege they were not given a hearing, is now being probed at the Chennai patent office. ... Livemint Press Release: Dr. Hans-Joachim Bohm Named President of Roche Palo … - Dec 11, 2006 Medicines discovered at Roche Palo Alto include CellCept(R) (mycophenolate mofetil), Valcyte(R) (valganciclovir) and Naprosyn(R) (naproxen). ... Pay-Per-View - PR Newswire - HighBeam Research Leading immunosuppressant CellCept® significantly extends the... - Oct 19, 2005 Valcyte was developed for the prevention of cytomegalovirus, a dangerous viral infection associated with transplantation. In addition, Roche supports basic ... eurekalert.org Liver transplant patients gain same benefits from CellCept® as kidney... - May 25, 2005 Valcyte was developed for the prevention of cytomegalovirus, a dangerous viral infection associated with transplantation. In addition, Roche supports basic ... eurekalert.org COMUNICADO: Los pacientes de transplante conservan sus nuevos … - Jul 24, 2006 Valcyte fue desarrollado para la prevención de citomegalovirus, una peligrosa infección viral asociada con el transplante. ... elEconomista.es Swiss drug company employs 370 at its site in Boulder. - Jul 23, 2005 Along with Fuzeon, the 370-employee Roche Colorado produces Valcyte, an antiviral agent; Invirase, a protease inhibitor to fight the onset of AIDS in ... Free with registration - Daily Camera - AccessMyLibrary.com El trasplante de sangre de cordón umbilical cuadruplica la probabilida... - Mar 10, 2006 ...una de las infecciones más frecuentes e importantes en TSCU; valganciclovir (comercializado por Roche con el nombre de Valcyte®) es un fármaco eficaz ... acceso.com New Therapy for Chronic Fatigue Syndrome to Be Tested at Stanford - Jan 8, 2007 Montoya has received a $1.3 million grant from Roche Pharmaceutical, which manufactures the drug under the brand name Valcyte, to conduct a randomized, ... Genetic Engineering News - Genetic Engineering News (press release) Antivirals cope with influenza, cytomegalovirus and varicella-zoster... - May 1, 2005 MHE Source: Treatment Guidelines from The Medical Letter, Vol 3 (32) April 2005 Drugs for Cytomegalovirus DRUGS ADULT DOSAGE Valganciclovir - Valcyte 900 mg ... Free with registration - Managed Healthcare Executive - AccessMyLibrary.com HACIA LA PROFILAXIS UNIVERSAL EN LA PREVENCIÓN DEL … - Apr 10, 2006 ...de un profármaco del ganciclovir, que es el éster de valina del ganciclovir o valganciclovir (comercializado por Roche con el nombre de Valcyte®). ... acceso.com New Therapy for Chronic Fatigue Syndrome to Be Tested at Stanford – … - Jan 17, 2007 Dr. Montoya has received a $1.3 million grant from Roche Pharmaceutical, which manufactures the drug under the brand name Valcyte®, to conduct a randomized, ... ProHealth Interactive Agencies—Runner-up: OTOi - Apr 2, 2007 OTOi created brand guidelines and Web sites for three of Roche's leading brands—CellCept, Valcyte and Zenapax—targeting physicians and patients. ... BtoB Magazine Treatments for chronic fatigue syndrome - Sep 21, 2008 The most watched study on the subject, headed by Dr. Jose Montoya of Stanford University, is currently testing the effectiveness of the potent drug Valcyte ... SheKnows.com How to take Tenofovir from Consumer Reports Health. - Jan 6, 2007 ...and valganciclovir (Valcyte); aspirin and other nonsteroidal antiinflammatory medications (NSAIDs) such as indomethacin (Indocin); didanosine (Videx); ... consumerreports.org India: Generics And Innovators - Saying I Do And Doing Battle - Aug 12, 2008 Roche's patent on "Valcyte" (valganciclovir), which survived pre-grant opposition, has been opposed by the Delhi Network of Positive People (DNP+) and a ... Mondaq News Alerts - Mondaq News Alerts (Registration) Infringement Interplay - Jul 21, 2008 Cipla, in its desire to launch a cheaper version of Roche's patented anti-retroviral valcyte, may have to battle the Indian authorities yet again. ... International Law Office El uso de valganciclovir en niños sometidos a un trasplante hepático ... - Jul 26, 2006 El objetivo fundamental del estudio era el de valorar la eficacia y seguridad del valganciclovir (comercializado por Roche con el nombre de Valcyte®) para ... acceso.com Roche pleases investors with 15% hike in first-half sales and strong ... - Jul 30, 2007 Valcyte (valganciclovir) and Cymevene (ganciclovir), for the prevention and treatment of cytomegalovirus disease in transplant patients and people with ... $9.94 - Pharma Marketletter - Alacra Store Report from: India. - Mar 1, 2008 ...on its bird-flu drug "Oseltamivir" and Ranbaxy has challenged the decision to grant a patent for Roche's anti-infection drug "Valcyte" in India. ... $9.94 - Pharmaceutical Technology - Alacra Store FDA approves generic version of Videx EC delayed release capsules.( … - Apr 1, 2005 Examples of these drugs include Zovirax (acyclovir) or its generic version acyclovir, Valtrex (valacyclovir), Cytovene (ganciclovir), Valcyte ... Pay-Per-View - HIV Treatment: ALERTS! - HighBeam Research Yellow-white retinal lesion in a 48-year-old woman.(Photo Quiz) - Aug 15, 2007 ...(3) Oral formulations of ganciclovir and valganciclovir (Valcyte) are available, allowing for maintenance treatment without the need for intravenous access. ... $4.95 - American Family Physician - ECNext HIV guidelines. - Feb 28, 2005 New treatment guidelines recommend Valcyte (Hoffmann-La Roche Inc.) for AIDS-related cytomegalovirus retinitis. The positive recommendations have been ... $9.94 - Chain Drug Review - Alacra Store Article: HIV guidelines.(RXs)(Human Immunodeficiency Virus)(Brief … - Feb 28, 2005 New treatment guidelines recommend Valcyte (Hoffmann-La Roche Inc.) for AIDS-related cytomegalovirus retinit... Pay-Per-View - Chain Drug Review - HighBeam Research Factiva Search - Feb 28, 2005 New treatment guidelines recommend Valcyte (Hoffmann-La Roche Inc.) for AIDS-related cytomegalovirus retinitis. The ... Copyright 2005 Gale Group Inc. All ... Pay-Per-View - Chain Drug Review - Factiva, from Dow Jones Factiva Search - Mar 1, 2005 2005 MAR 1 - (NewsRx.com & NewsRx.net) -- VALCYTE (valganciclovir), a potent oral treatment for AIDS-related cytomegalovirus ... ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Generics And Innovators - Saying I Do And Doing Battle. - Dec 8, 2008 Roche's patent on "Valcyte" (valganciclovir), which survived pre-grant opposition, has been opposed by the Delhi Network of Positive People (DNP+) and a ... $9.94 - Mondaq Business Briefing - Alacra Store Factiva Search - Mar 4, 2005 2005 MAR 4 - (NewsRx.com & NewsRx.net) -- VALCYTE (valganciclovir), a potent oral treatment for AIDS-related cytomegalovirus ... ... Pay-Per-View - Genomics & Genetics Weekly - Factiva, from Dow Jones Factiva Search - Mar 1, 2005 2005 MAR 1 - (NewsRx.com & NewsRx.net) -- VALCYTE (valganciclovir), a potent oral treatment for AIDS-related cytomegalovirus ... ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones Global top 300 brand-name pharmaceuticals by sales, manufacturer, and... - Apr 28, 2008 Loestrin 24 FE 00430053014 212 Janssen Risperdal 50458030104 213 Novo Nordisk Novolog Mix 70/30 00169368512 214 Roche Valcyte 00004003822 215 MSD Cozaar ... $20.00 - Chain Drug Review - Alacra Store Pharmaceutical: top 50 packages.(TOP 200 PACKAGERS)(Illustration) | … - Jul 1, 2005 4 Roche Holding Ltd. Boniva; CellCept; Fuzeon; (9) Basel, Switzerland / Nutley, Kytril; Pegasys; Tamiflu; Valcyte; Xeloda; Zenapax 5 Merck & Co. ... Pay-Per-View - Food & Drug Packaging - HighBeam Research Pharmaceutical: top 50 packages.(TOP 200 PACKAGERS)(Illustration) - Jul 1, 2005 4 Roche Holding Ltd. Boniva; CellCept; Fuzeon; (9) Basel, Switzerland / Nutley, Kytril; Pegasys; Tamiflu; Valcyte; Xeloda; Zenapax 5 Merck & Co. ... $4.95 - Food & Drug Packaging - ECNext Brand Names/Synonyms: Valcyte is also known by the following brand names and/or synonymsCytovene; Cytovene Iv; Cytovene-Iv; GA2; GCV & MSL; Ganciclovir; Ganciclovir Sodium; Gancyclovir; Hydroxyacyclovir; Valcyte; Vitrasert Drug Category: Valcyte is categorized under the following by the FDA: Antivirals; Nucleosides and Nucleotides (08:18.32); ATC:J05AB06; ATC:J05AB14; Dosage Forms: CAPSULE; IMPOLANT; POWDER FOR SOLUTION Absorption: Poorly absorbed orally, bioavailability is 6% to 9% Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 2-[(2-amino-6-hydroxy-purin-9-yl)methoxy]propane-1,3-diol |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |